Keratinocyte growth factor (KGF), also known as palifermin or FGF-7, is part of the FGF family, and KGF binding to its receptor induces epithelial cell proliferation, differentiation, and migration. With a high level of receptor specificity, it performs important roles in maintaining tissue regeneration and mucosal barrier integrity.
Because of these unique properties, researchers developed human recombinant KGF (palifermin) to promote the growth of damaged epithelial tissues. The use of palifermin has been demonstrated to be effective in attenuating chemotherapy- and radiotherapy-induced oral mucositis (OM) and improving patients' quality of life. KGF-derived proteins have been used for a variety of purposes and in a wide range of diseases, such as wound healing, tissue repair, diabetes, bladder and lung injuries, and gastrointestinal mucositis.
Application of KGF
Palifermin (Kepivance)
As a recombinant truncated human KGF comprising 140 amino acids, palifermin (Kepivance) is the first active ingredient approved for the prevention of oral mucositis in haematopoietic stem cell transplant (HSCT) patients. In Palifermin, what has been removed includes the KGF-1 signalling peptide and the subsequent 23 amino acid residues, resulting in a 10-fold increase in the specific activity of rhKGF compared to isolated KGF from fibroblasts. It is produced in Escherichia coli (E. coli) by recombinant DNA technology and developed by Biovitrum who focuses on organ drugs.
Yaohai Bio-Pharma Offers One-Stop CDMO Solution for KGF
Keratinocyte growth factor (KGF) Pipelines
|
Types
|
Name
|
Alternative Name
|
Expression System
|
Indication
|
Manufacturer
|
Stage
|
|
KGF-1, FGF-7
|
Palifermin
|
AMJ 9701, Kepivance
|
E. coli
|
Stomatitis
|
Swedish Orphan Biovitrum AB
|
Approval
|
|
KGF-1, FGF-7
|
Palifermin biosimilar
|
Pending update
|
Pending update
|
Mucositis
|
Chengdu Zhitian Biological Engineering
|
Phase II
|
|
KGF-1, FGF-7
|
Recombinant Human Keratinocyte Growth Factor
|
Pending update
|
Pending update
|
Pending
|
Jiangsu Aosaikang Pharmaceutical
|
Phase I
|
|
KGF-2
|
Recombinant human keratinocyte growth factor-2
|
Pending update
|
Pending update
|
Burn
|
Shanghai Newsummit Biopharma
|
Phase III
|
|
KGF-2
|
Recombinant human keratinocyte growth factor-2
|
Pending update
|
Pending update
|
Burn
|
Wuhan Optics Valley New Medicine Incubation Public Service Platform Co Ltd
|
Phase III
|
|
KGF-2
|
Recombinant human keratinocyte growth factor-2
|
Pending update
|
Pending update
|
Corneal injury, Corneal disease, Keratitis
|
Guangzhou Jida Gene Pharmacy Engineering Research Center Co Ltd | Wenzhou Medical University
|
Phase I
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
